Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17643986rdf:typepubmed:Citationlld:pubmed
pubmed-article:17643986lifeskim:mentionsumls-concept:C0038760lld:lifeskim
pubmed-article:17643986lifeskim:mentionsumls-concept:C1413555lld:lifeskim
pubmed-article:17643986lifeskim:mentionsumls-concept:C2927148lld:lifeskim
pubmed-article:17643986lifeskim:mentionsumls-concept:C0243072lld:lifeskim
pubmed-article:17643986pubmed:issue18lld:pubmed
pubmed-article:17643986pubmed:dateCreated2007-8-22lld:pubmed
pubmed-article:17643986pubmed:abstractTextA novel series of sulfonamide derivatives 3, the CB(2) receptor agonists, was synthesized and evaluated for activity against the human CB(2) receptor. We first identified sulfonamide 3a, which was obtained by random screening of our in-house chemical library as a moderately active (CB(2) IC(50)=340nM) CB(2) receptor agonist. We then attempted to test its analogues to identify compounds with a high affinity for the CB(2) receptor. One of these, compound 3f, exhibited high affinity for the human CB(2) receptor (IC(50)=16nM) and high selectivity for CB(2) over CB(1) (CB(1) IC(50)/CB(2)IC(50)=106), and behaved as a full CB(2) receptor agonist in the [(35)S]GTPgammaS binding assay (CB(2) EC(50)=7.2nM, E(max)=100%).lld:pubmed
pubmed-article:17643986pubmed:languageenglld:pubmed
pubmed-article:17643986pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17643986pubmed:citationSubsetIMlld:pubmed
pubmed-article:17643986pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17643986pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17643986pubmed:statusMEDLINElld:pubmed
pubmed-article:17643986pubmed:monthSeplld:pubmed
pubmed-article:17643986pubmed:issn0960-894Xlld:pubmed
pubmed-article:17643986pubmed:authorpubmed-author:TodaYoshihisa...lld:pubmed
pubmed-article:17643986pubmed:authorpubmed-author:OhtaHiroshiHlld:pubmed
pubmed-article:17643986pubmed:authorpubmed-author:SaitoShujiSlld:pubmed
pubmed-article:17643986pubmed:authorpubmed-author:TomishimaYasu...lld:pubmed
pubmed-article:17643986pubmed:authorpubmed-author:IshizakaTomok...lld:pubmed
pubmed-article:17643986pubmed:authorpubmed-author:YoshinagaMits...lld:pubmed
pubmed-article:17643986pubmed:authorpubmed-author:MoritaAkiAlld:pubmed
pubmed-article:17643986pubmed:issnTypePrintlld:pubmed
pubmed-article:17643986pubmed:day15lld:pubmed
pubmed-article:17643986pubmed:volume17lld:pubmed
pubmed-article:17643986pubmed:ownerNLMlld:pubmed
pubmed-article:17643986pubmed:authorsCompleteYlld:pubmed
pubmed-article:17643986pubmed:pagination5133-5lld:pubmed
pubmed-article:17643986pubmed:meshHeadingpubmed-meshheading:17643986...lld:pubmed
pubmed-article:17643986pubmed:meshHeadingpubmed-meshheading:17643986...lld:pubmed
pubmed-article:17643986pubmed:meshHeadingpubmed-meshheading:17643986...lld:pubmed
pubmed-article:17643986pubmed:meshHeadingpubmed-meshheading:17643986...lld:pubmed
pubmed-article:17643986pubmed:year2007lld:pubmed
pubmed-article:17643986pubmed:articleTitleSulfonamide derivatives as new potent and selective CB2 cannabinoid receptor agonists.lld:pubmed
pubmed-article:17643986pubmed:affiliationMedicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd, 1-403 Yoshino-cho, Kita-ku, Saitama-shi, Saitama 331-9530, Japan. hiroshi.ohta@po.rd.taisho.co.jplld:pubmed
pubmed-article:17643986pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:17643986lld:chembl
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17643986lld:pubmed